TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25531536

Group type: EXPERIMENTAL
Intervention: Voucher-based treatment with motivational counseling (14 days of vouchers for complete smoking abstinence after a 5-day smoking reduction lead-in period)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Voucher-based treatment with motivational counseling (vouchers not contingent on abstinence)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Intolerance for Smoking Abstinence Discomfort (IDQ-S) and nicotine dependence severity (FTND)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Pretreatment motivation to quit smoking
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Lower withdrawal intolerance
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Higher withdrawal intolerance pretreatment
Number of subjects: 184
Study: 23884486

Group type: EXPERIMENTAL
Intervention: Itraconazole 200-mg tablet QD for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole 100-mg capsules QD for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20980196

Group type: EXPERIMENTAL
Intervention: tDCS with round electrodes
Number of subjects: 12

Group type: COMPARATOR
Intervention: tDCS with rectangular electrodes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: tRNS with round electrodes
Number of subjects: 12

Group type: COMPARATOR
Intervention: tRNS with rectangular electrodes
Number of subjects: 12
Study: 19302902

Group type: EXPERIMENTAL
Intervention: Cefepime IV at a dose of 1 g q8h
Number of subjects: 120

Group type: COMPARATOR
Intervention: Other appropriate antimicrobials
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All patients studied
Number of subjects: 120
Study: 17403273

Group type: EXPERIMENTAL
Intervention: Inulin (10 g/d) for 21 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lightly cooked cabbage (microwaved for 2 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no inulin) for 21 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fully cooked cabbage (microwaved for 5.5 min)
Number of subjects: 12
Study: 15509187

Group type: EXPERIMENTAL
Intervention: fenofibrate 160 mg plus colesevelam HCl 3750 mg (6 x 625 mg tablets) administered with breakfast
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: fenofibrate 160 mg administered with breakfast, followed 4 hours later by colesevelam HCl 3750 mg (6 x 625 mg tablets) administered with lunch
Number of subjects: 30

Group type: COMPARATOR
Intervention: fenofibrate 160 mg administered with breakfast
Number of subjects: 30
Study: 11813601

Group type: EXPERIMENTAL
Intervention: Locoregional immunochemotherapy combined with systemic chemotherapy (Group A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Systemic immunotherapy combined with systemic chemotherapy (Group B)
Number of subjects: 122
Study: 9492130

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide/50% oxygen
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 30
Study: 8064995

Group type: EXPERIMENTAL
Intervention: IINS (Insulin + Amino Acids)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ICON (Control with Amino Acids)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IIINS (Insulin + Higher Nitrogen Load)
Number of subjects: 32

Group type: COMPARATOR
Intervention: IICON (Control with Higher Nitrogen Load)
Number of subjects: 32
Study: 2737711

Group type: EXPERIMENTAL
Intervention: 10 mmol/day calcium carbonate (CaCO3)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 20 mmol/day calcium carbonate (CaCO3)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Rechallenge with 20 mmol/day CaCO3
Number of subjects: 95
Study: 30049269

Group type: EXPERIMENTAL
Intervention: Quadriceps strength (strongest quartile)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Hamstrings strength (strongest quartile)
Number of subjects: 252
Study: 28544896

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 151
Study: 26218035

Group type: EXPERIMENTAL
Intervention: Eight revised Forever Free booklets (n = 703)
Number of subjects: 1407

Group type: COMPARATOR
Intervention: Single leaflet (n = 704)
Number of subjects: 1407
Study: 24156290

Group type: EXPERIMENTAL
Intervention: Prescriptive dietary intervention
Number of subjects: 109
Study: 20882421

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg of elemental zinc per day for 5 days)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo control (equal amount to zinc, modified for taste, smell, color, and consistency)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 106
Study: 18235194

Group type: EXPERIMENTAL
Intervention: Specialized training for phonologic awareness
Number of subjects: 218

Group type: COMPARATOR
Intervention: General perception training
Number of subjects: 218
Study: 15963089

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 0.5 mg sublingual
Number of subjects: 29

Group type: COMPARATOR
Intervention: Atenolol 100 mg daily for 4 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mental activation, standing, exercise
Number of subjects: 29
Study: 12870063

Group type: EXPERIMENTAL
Intervention: Intravenous penicillin, 6 million units per day (one million unit every four hours) for seven days
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (without penicillin)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 253
Study: 10571602

Group type: EXPERIMENTAL
Intervention: Simethicone (84 mg t.d.s.)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Cisapride (10 mg t.d.s.)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 173

Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 173
Study: 8712383

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) 300,000 U infused in Groups C and D
Number of subjects: 39
Study: 1905214

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition and sucralfate (1 g by nasogastric tube every 4 hrs)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition and ranitidine (50 mg iv every 6 hrs)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Total parenteral nutrition and sucralfate
Number of subjects: 97

Group type: COMPARATOR
Intervention: Total parenteral nutrition and ranitidine
Number of subjects: 97
Study: 6668226

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate with riboflavin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 30857773

Group type: EXPERIMENTAL
Intervention: Baby Triple P intervention (4 hospital-based and 4 home-phone sessions)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 384
Study: 30131262

Group type: EXPERIMENTAL
Intervention: Acupuncture (indwelling press needles)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (sham needles)
Number of subjects: 30
Study: 26505163

Group type: EXPERIMENTAL
Intervention: Δ9‐THC (8 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active placebo (5 mg/10 mg diazepam)
Number of subjects: 24
Study: 25194996

Group type: EXPERIMENTAL
Intervention: Primary closure of buccal mucosal graft harvest site
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonclosure of buccal mucosal graft harvest site
Number of subjects: 34
Study: 22265989

Group type: EXPERIMENTAL
Intervention: Fluoride-free toothpaste (BT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (BFT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brushing with deionised water (BW)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immersion in fluoride-free toothpaste (IFT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immersion in fluoride toothpaste (IT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immersion in deionised water (IW)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brushing with fluoride toothpaste (BT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste (BFT)
Number of subjects: 36
Study: 20226618

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES) implantation
Number of subjects: 450

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) implantation
Number of subjects: 450
Study: 17663046

Group type: EXPERIMENTAL
Intervention: Millimeter-range electromagnetic radiation therapy
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Millimeter-range noise electromagnetic radiation
Number of subjects: 152
Study: 17966001

Group type: EXPERIMENTAL
Intervention: Lubinus Flanged Anti‐Luxation cup (FAL)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Lubinus Standard Eccentric cup (Standard)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (FAL and Standard)
Number of subjects: 53
Study: 14682195

Group type: EXPERIMENTAL
Intervention: Preventive measures including physical exercise and protein energy intake
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not receiving preventive measures)
Number of subjects: 102
Study: 11039135

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping of 45 s
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed cord clamping of 20 s
Number of subjects: 40
Study: 9177976

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.05 mg/kg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol (40 ng/kg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of low dose oxandrolone and oestrogen
Number of subjects: 19
Study: 1609044

Group type: EXPERIMENTAL
Intervention: Bovine cortex phosphatidylserine (BC‐PS; 100 mg t.i.d.)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 3907394

Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline sulphate 5 mg twice a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ordinary tablets 2.5 mg three times a day
Number of subjects: 30
Study: 31774980

Group type: EXPERIMENTAL
Intervention: Post-clinical cohort scores for the IPAS subdomain of teamwork, roles, and responsibilities
Number of subjects: 865

Group type: COMPARATOR
Intervention: Baseline and post-didactic cohort scores
Number of subjects: 865
Study: 28369652

Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 62

Group type: COMPARATOR
Intervention: Late feeding
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Early feeding (very preterm)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Late feeding (very preterm)
Number of subjects: 62
Study: 27015546

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (5 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous dexamethasone (5 mg)
Number of subjects: 150
Study: 24693959

Group type: EXPERIMENTAL
Intervention: Acupuncture plus interlaminar epidural steroid injection
Number of subjects: 14

Group type: COMPARATOR
Intervention: Interlaminar epidural steroid injection
Number of subjects: 14
Study: 22861076

Group type: EXPERIMENTAL
Intervention: Topical lidocaine patches (700 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40
Study: 20433740

Group type: EXPERIMENTAL
Intervention: Early developmental intervention plus health and safety counseling
Number of subjects: 431

Group type: COMPARATOR
Intervention: Health and safety counseling only (Control)
Number of subjects: 431
Study: 18568553

Group type: EXPERIMENTAL
Intervention: 5M CRT monitors
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3M LCD monitors
Number of subjects: 100
Study: 16005120

Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional subunit vaccine
Number of subjects: 0
Study: 12426518

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered once weekly (n = 17)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered 3 times weekly (n = 15)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Epoetin administered 3 times weekly (n = 15)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (once and three times weekly) and Epoetin (three times weekly)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa and Epoetin
Number of subjects: 47
Study: 10233652

Group type: EXPERIMENTAL
Intervention: Chart as an aide memoire for topical medications
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no chart used)
Number of subjects: 100
Study: 7805919

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) injection (1 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic salpingotomy
Number of subjects: 40
Study: 1655177

Group type: EXPERIMENTAL
Intervention: Piroxicam 5 mg daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Seasonal variation
Number of subjects: 55
Study: 6336951

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 1.5 g three times daily for 5 days starting on the first day of menstruation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS) 50 mg three times on the first day followed by 25 mg three times daily for 4 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30612372

Group type: EXPERIMENTAL
Intervention: NAHSIT 93-96 (N=821)
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: NAHSIT 05-08 (N=780)
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Participants with alcohol consumption, betel quid chewing, or cigarette smoking
Number of subjects: 1601
Study: 29539585

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (70% of VO2max)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low intensity aerobic exercise (30% of VO2max)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Exposure-based Cognitive Behavioral Therapy (eb-CBT)
Number of subjects: 77
Study: 27283792

Group type: EXPERIMENTAL
Intervention: 30 μg subcutaneous (s.c.) relamorelin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24284470

Group type: EXPERIMENTAL
Intervention: Oculomotor training (OMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham training (ST)
Number of subjects: 12
Study: 22262484

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion during high sodium intake (HS; 300 mmol sodium/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion during low sodium intake (LS; 30 mmol sodium/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline conditions
Number of subjects: 0
Study: 19075273

Group type: EXPERIMENTAL
Intervention: Chemotherapy (first cycle)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Chemotherapy (second cycle)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Baseline SUV < 3.0
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Threshold of 45% decrease in SUV
Number of subjects: 104
Study: 17524265

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg daily
Number of subjects: 332

Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Telbivudine and Lamivudine
Number of subjects: 332
Study: 15948744

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily
Number of subjects: 293

Group type: COMPARATOR
Intervention: oxybutynin 3 mg three times daily
Number of subjects: 293

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 293
Study: 12077732

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (8% carbohydrate) for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (normal diet)
Number of subjects: 12
Study: 9462396

Group type: EXPERIMENTAL
Intervention: Marsupialization (MS group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Leaving wounds open (LO group)
Number of subjects: 103
Study: 7666089

Group type: EXPERIMENTAL
Intervention: PVI 5‐FU 300 mg/m2/d plus IFN 5 MU subcutaneously three times weekly
Number of subjects: 160

Group type: COMPARATOR
Intervention: PVI 5‐FU alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PVI 5‐FU plus IFN
Number of subjects: 160
Study: 2759973

Group type: EXPERIMENTAL
Intervention: Ephedrine-caffeine mixture (1 mg/kg ephedrine, 2.5 mg/kg caffeine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 778656

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31612188

Group type: EXPERIMENTAL
Intervention: 100 mg rectal diclofenac
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: 50 mg oral diclofenac
Number of subjects: 100

Group type: COMPARATOR
Intervention: 75 mg/3 ml intramuscular diclofenac sodium
Number of subjects: 100

Group type: COMPARATOR
Intervention: 75 mg/3 ml intravenous diclofenac
Number of subjects: 100
Study: 28558714

Group type: EXPERIMENTAL
Intervention: ProF-Cog intervention including falls risk assessment, tailored intervention (dementia care mapping, comprehensive geriatric assessment, occupational therapy, twice-weekly exercise for 6 months)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Usual care without falls risk assessment
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: ProF-Cog intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: ProF-Cog intervention and usual care
Number of subjects: 191
Study: 26075486

Group type: COMPARATOR
Intervention: Monetary reinforcement and response cost
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined effect of reinforcement and MPH
Number of subjects: 40
Study: 23485054

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21439546

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 μg/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 43
Study: 19436663

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg) once daily
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 16393880

Group type: EXPERIMENTAL
Intervention: DHEA supplementation
Number of subjects: 0
Study: 16195088

Group type: EXPERIMENTAL
Intervention: Real left prefrontal high‐frequency rTMS (20 trains of 10 s, 60‐s interval, 10 Hz, 90% of motor threshold)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study: 15982126

Group type: EXPERIMENTAL
Intervention: Irrelevant spatial mismatch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irrelevant functional mismatch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional relation context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial relation context
Number of subjects: 0
Study: 10328277

Group type: EXPERIMENTAL
Intervention: Rectal diazepam (DZP) gel
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 7743305

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oesophageal transection
Number of subjects: 41
Study: 2147612

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7001487

Group type: EXPERIMENTAL
Intervention: 150 mg protacine 3-times daily for 21 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: 200 mg oxyphenbutazone 3-times daily for 21 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 150 mg protacine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 200 mg oxyphenbutazone
Number of subjects: 30
Study: 31809955

Group type: EXPERIMENTAL
Intervention: Torsemide (0.1 mg/kg PO q 12 h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Furosemide (2.0 mg/kg PO q 12 h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diuretic groups (Torsemide and Furosemide)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29036203

Group type: EXPERIMENTAL
Intervention: Cooling the lower abdomen with an 8.6°C icepack during the first 2 hours after placental delivery
Number of subjects: 160

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 160
Study: 26783233

Group type: EXPERIMENTAL
Intervention: Systematic clinical testing including exercise testing, drug provocation, advanced cardiac imaging, and genetic testing.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator therapy.
Number of subjects: 200
Study: 25035340

Group type: EXPERIMENTAL
Intervention: DSE RAM System intervention for risk assessment and workstation modification
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: DSE RAM System intervention for promoting behavior change
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: DSE RAM System intervention
Number of subjects: 186
Study: 22622147

Group type: EXPERIMENTAL
Intervention: XELOX plus bevacizumab using a standard triweekly cycle (Q3W)
Number of subjects: 435

Group type: COMPARATOR
Intervention: XELOX plus bevacizumab using a dose-dense biweekly cycle (Q2W)
Number of subjects: 435
Study: 20642467

Group type: EXPERIMENTAL
Intervention: Amalgomer CR
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 100
Study: 17546705

Group type: EXPERIMENTAL
Intervention: Offered prenatal screening (n = 1031)
Number of subjects: 1418

Group type: EXPERIMENTAL
Intervention: Negatively screened women (n = 466)
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Ultrasound screening (n = 285)
Number of subjects: 1418